It has to be noted that both air monitoring and the spirometry were performed during the whole working week. Table 5 shows control groups: 13 unexposed subjects and 12 patients with occupational asthma
not exposed to isocyanates (baker’s asthma). None of www.selleckchem.com/products/ch5183284-debio-1347.html the unexposed controls had MDI-specific IgE antibodies, one had sIgG binding at a low level (3.3 mg/L), and a similar result showed one control baker’s asthma patient. Table 5 Demographic and Ivacaftor solubility dmso clinical and functional characteristics of two control groups: healthy subjects (group c) and asthma patients, not exposed to isocyanates (group D, patients with baker’s asthma) Subject Demographic data Immunological status Lung function MDI-specific antibodies Final clinical diagnosis No. # Sex Age Smo-king status Comm. allerg. Total IgE kU/L FVC % pred FEV1 % pred. NS-BHR
MDI-sIgE kU/L MDI-sIgG mg/L Group C: Unexposed healthy control subjects 19 F 28 No Neg. n.d. n.d. n.d. n.d. <002 <3 H 20 M 28 No Pos. n.d. n.d. n.d. n.d. Rabusertib <0.02 <3 H 21 F 50 No Pos. n.d. n.d. n.d. n.d. <0.02 3.3 H 22 F 54 No Neg. n.d. n.d. n.d. n.d. <0.02 <3 H 23 M 56 No Neg. n.d. n.d. n.d. n.d. <0.02 <3 H 24 M 30 No Pos. 67 n.d. n.d. n.d. <0.02 <3 H 25 F 31 No Neg. 128 n.d. n.d. n.d. <0.02 <3 H 26 M 55 Ex Neg. 27 n.d. n.d. n.d. <0.02 <3 H 27 F 57 No Neg. 272 n.d. n.d. n.d. <0.02 <3 H 28 F 61 No Neg. 7.3 n.d. n.d. n.d. <0.02 <3 H 29 F 47 No Pos. 870 n.d. n.d. n.d. <0.02 <3 H 30 F 43 Yes Neg. 33 n.d. n.d. n.d. <0.02 <3 H 31 M 40 No Pos. much 42 n.d. n.d. n.d. <0.02 <3 H Group D. Asthma patients not exposed to isocyanates 32 M 42 No Pos 83 88 86 neg. <0.02 <3 OAB 33 M 40 No Pos 135 94 92 Pos. <0.02 <3 OAB 34 M 44 No Pos 893 106 90 Pos. <0.02 <3 OAB 35 F 62 Ex Neg 65 115 105 Neg. <0.02 <3 OAB 36 F 41 Yes Pos 197 112 111 Pos. <0.02 <3 OAB 37 M 57 Yes Pos 246 95 80 Pos. <0.02 <3 OAB 38 M 56 Ex Neg 332 85 81 Neg. <0.02 <3 OAB 39 M 50 Ex Pos 33 83 66 Pos. <0.02 <3
OAB 40 M 41 No Pos 22 108 82 Neg. <0.02 <3 OAB 41 M 45 No Pos 101 102 98 Pos. <0.02 <3 OAB 42 M 39 No Pos 323 111 97 Neg. <0.02 <3 OAB 43 M 50 No Neg 153 107 75 Pos. <0.02 4.86 OAB See Table 1 for details, OAB, occupational baker’s asthma; H, healthy Discussion Are the antibody data valuable for the MDI-asthma diagnosis? We could confirm our earlier studies (Baur 1983, 2007), showing the correlation between specific IgE antibodies and the diagnosis of isocyanate asthma using validated fluorescence immunoassay and detailed comprehensive clinical diagnosis.